The Money Show hears about Cilo Cybin Pharmaceutical’s latest plans from CEO Gabriel Theron.

© Eric Limon / 123rf.com

Cilo Cybin Pharmaceutical will be the first cannabis and cannabis products manufacturer in South Africa to list on the Johannesburg Stock Exchange (JSE).

Founder and CEO Gabriel Theron says the company has been inundated with requests for information from both the media and investors since Bloomberg News published the story in August.

It got to the point where we had to create an Investors page on our website … as things get introduced we will keep them updated.

Gabriel Theron, Founder and CEO – Cilo Cybin Pharmaceutical

We started with the University of Technology – it is our partner in terms of the creation of our formulations and our product development especially for cannabis products, so that we are not just another CBD brand or a THC brand on the market.

Gabriel Theron, Founder and CEO – Cilo Cybin Pharmaceutical

We are in the final stages of our validation runs and will go into production on November 1st. We pushed for some products on the shelves on December 1st, your non-schedule products … the schedule products will be available but only with a doctor’s prescription … slightly longer process.

Gabriel Theron, Founder and CEO – Cilo Cybin Pharmaceutical

Theron says there is a process to get the medical device to the patient, but it is a time consuming one.

The company recently had a discussion with the regulator on how to speed this up.

It is available, but not readily available.

Gabriel Theron, Founder and CEO – Cilo Cybin Pharmaceutical

Given the choice, he would list Cilo Cybin next month, but legal advisors have suggested it will take another 4-6 months, Theron says.

It’s a much bigger game than that [the JSE]. Listing on the JSE is our first step … raising the funds to acquire all of the assets we need … It’s not just South African assets, and not just cannabis assets …

Gabriel Theron, Founder and CEO – Cilo Cybin Pharmaceutical

Listen to the interview with Theron on The Money Show:


More from business

More of lifestyle